Overview

Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.
Phase:
Phase 4
Details
Lead Sponsor:
Young-Hak Kim, MD, PhD